Lyka Labs Limited (BSE: 500259, NSE: LYKALABS) has announced a significant development in its proposed merger with Lyka Exports Limited. The National Company Law Tribunal (NCLT) Ahmedabad Bench has reserved its order for formal pronouncement on the merger, indicating 'no objection' to the scheme of amalgamation.

Key Highlights

• The NCLT hearing took place on August 7, 2025
• Lyka Labs Limited is the transferee company, while Lyka Exports Limited is the transferor company
• The NCLT has reserved its order, stating 'no objection' to the merger scheme
• Formal pronouncement of the order is pending

Merger Details

The proposed merger between Lyka Labs Limited and Lyka Exports Limited has reached a crucial stage. The Joint Petition filed by both companies was heard by the NCLT Ahmedabad Bench, which has jurisdiction over both the transferor and transferee companies.

NCLT's Stance

During the hearing on August 7, 2025, the NCLT reserved its order for formal pronouncement. Importantly, the tribunal has indicated 'no objection' to the scheme of amalgamation, suggesting a positive outlook for the merger's approval.

Company's Response

Kunal Gandhi, Managing Director & CEO of Lyka Labs Limited, stated in a regulatory filing, "The company will separately make necessary disclosure once the NCLT order is formally pronounced." This approach underscores the company's commitment to transparency and compliance with regulatory requirements.

Market Impact

While the final order is yet to be formally pronounced, the NCLT's 'no objection' stance is likely to be viewed positively by investors and stakeholders. The merger, if approved, could potentially lead to synergies and enhanced operational efficiencies for the combined entity.

Next Steps

Investors and market participants will be keenly awaiting the formal pronouncement of the NCLT order. Lyka Labs has assured that it will make the necessary disclosures once the order is officially pronounced.

The company has made this information available on its website ( www.lykalabs.com ) and has duly informed the stock exchanges as part of its regulatory obligations under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

As the merger process progresses, stakeholders will be watching closely for further developments and the potential impact on Lyka Labs' future operations and market position.

Lyka Labs Limited , a prominent pharmaceutical company, has made several significant announcements following its recent Board of Directors meeting. The company has released its unaudited financial results for the quarter ended June 30, 2025, and disclosed important changes in its management structure and internal audit processes.

Financial Results

The Board of Directors has approved and taken on record the unaudited financial results for the first quarter of the fiscal year 2025-26. These results, both standalone and consolidated, have been reviewed and are accompanied by a Limited Review Report. The detailed financial figures are available in the annexures of the company's official communication.

Management Changes

Resignation of Company Secretary

In a significant development, Mr. Shekhar R Singh, the Company Secretary and Compliance Officer of Lyka Labs, has tendered his resignation. Mr. Singh cited the pursuit of alternative career opportunities outside the organization as the reason for his departure.

Key points regarding Mr. Singh's resignation:

• The resignation was initially effective from the close of business hours on July 30, 2025.
• Mr. Singh has committed to continuing his responsibilities, including those related to the upcoming 46th Annual General Meeting (AGM).
• He will ensure a smooth and structured handover before his exit.
• The Board has accepted his resignation, effective from the close of business hours on August 1, 2025.
• The company has expressed appreciation for Mr. Singh's valuable contributions during his tenure.

Appointment of New Internal Auditor

In another strategic move, Lyka Labs has appointed a new internal auditor for the financial year 2025-26.

Details of the appointment:

• Firm: Sudit K Parekh & Co. LLP, Chartered Accountants
• Firm Registration Number: 110512W/ W100378
• Appointment Date: August 1, 2025
• Term: For the financial year 2025-26

Sudit K Parekh & Co. LLP is a Mumbai-based firm of practicing Chartered Accountants. The firm is known for offering a wide spectrum of services to its clientele and has significant experience in handling internal audit assignments. With highly qualified partners and an experienced team, the firm is well-positioned to support Lyka Labs in its internal audit functions.

Conclusion

These announcements reflect Lyka Labs' commitment to transparency and corporate governance. The company's proactive approach in managing leadership transitions and strengthening its internal audit processes demonstrates its focus on maintaining robust financial and operational standards. Investors and stakeholders will be keenly watching how these changes impact the company's performance in the coming quarters.